PratenseinCAS# 2284-31-3 |
Quality Control & MSDS
Number of papers citing our products
Chemical structure
3D structure
| Cas No. | 2284-31-3 | SDF | Download SDF |
| PubChem ID | 5281803 | Appearance | Powder |
| Formula | C16H12O6 | M.Wt | 300.3 |
| Type of Compound | Flavonoids | Storage | Desiccate at -20°C |
| Solubility | Soluble in Chloroform,Dichloromethane,Ethyl Acetate,DMSO,Acetone,etc. | ||
| Chemical Name | 5,7-dihydroxy-3-(3-hydroxy-4-methoxyphenyl)chromen-4-one | ||
| SMILES | COC1=C(C=C(C=C1)C2=COC3=CC(=CC(=C3C2=O)O)O)O | ||
| Standard InChIKey | FPIOBTBNRZPWJW-UHFFFAOYSA-N | ||
| Standard InChI | InChI=1S/C16H12O6/c1-21-13-3-2-8(4-11(13)18)10-7-22-14-6-9(17)5-12(19)15(14)16(10)20/h2-7,17-19H,1H3 | ||
| General tips | For obtaining a higher solubility , please warm the tube at 37 ℃ and shake it in the ultrasonic bath for a while.Stock solution can be stored below -20℃ for several months. We recommend that you prepare and use the solution on the same day. However, if the test schedule requires, the stock solutions can be prepared in advance, and the stock solution must be sealed and stored below -20℃. In general, the stock solution can be kept for several months. Before use, we recommend that you leave the vial at room temperature for at least an hour before opening it. |
||
| About Packaging | 1. The packaging of the product may be reversed during transportation, cause the high purity compounds to adhere to the neck or cap of the vial.Take the vail out of its packaging and shake gently until the compounds fall to the bottom of the vial. 2. For liquid products, please centrifuge at 500xg to gather the liquid to the bottom of the vial. 3. Try to avoid loss or contamination during the experiment. |
||
| Shipping Condition | Packaging according to customer requirements(5mg, 10mg, 20mg and more). Ship via FedEx, DHL, UPS, EMS or other couriers with RT, or blue ice upon request. | ||
| Description | 1. Pratensein has robust activation of acetylcholinesterase expression, the induction of acetylcholinesterase included the levels of mRNA, protein and enzymatic activity. 2. Pratensein can significantly ameliorate Aβ1-42-induced spatial learning and memory impairment through reducing neuroinflammation via inhibition of glial activation and NF-κB activation, and restoring synapse and BDNF levels, suggests that administration of pratensein could likely provide a therapeutic approach for AD. 3. Pratensein as a novel transcriptional up-regulator of scavenger receptor class B type I in HepG2 cells. 4. Pratensein can protect dopaminergic neurons against LPS-induced injury through inhibition of microglia activation and proinflammatory factors generation. |
| Targets | AChR | NF-kB | Beta Amyloid | TNF-α |
Pratensein Dilution Calculator
Pratensein Molarity Calculator
| 1 mg | 5 mg | 10 mg | 20 mg | 25 mg | |
| 1 mM | 3.33 mL | 16.65 mL | 33.3 mL | 66.6001 mL | 83.2501 mL |
| 5 mM | 0.666 mL | 3.33 mL | 6.66 mL | 13.32 mL | 16.65 mL |
| 10 mM | 0.333 mL | 1.665 mL | 3.33 mL | 6.66 mL | 8.325 mL |
| 50 mM | 0.0666 mL | 0.333 mL | 0.666 mL | 1.332 mL | 1.665 mL |
| 100 mM | 0.0333 mL | 0.1665 mL | 0.333 mL | 0.666 mL | 0.8325 mL |
| * Note: If you are in the process of experiment, it's necessary to make the dilution ratios of the samples. The dilution data above is only for reference. Normally, it's can get a better solubility within lower of Concentrations. | |||||
Calcutta University
University of Minnesota
University of Maryland School of Medicine
University of Illinois at Chicago
The Ohio State University
University of Zurich
Harvard University
Colorado State University
Auburn University
Yale University
Worcester Polytechnic Institute
Washington State University
Stanford University
University of Leipzig
Universidade da Beira Interior
The Institute of Cancer Research
Heidelberg University
University of Amsterdam
University of Auckland
TsingHua University
The University of Michigan
Miami University
DRURY University
Jilin University
Fudan University
Wuhan University
Sun Yat-sen University
Universite de Paris
Deemed University
Auckland University
The University of Tokyo
Korea University
- Aspartame
Catalog No.:BCC8836
CAS No.:22839-47-0
- Boc-D-Val-OH
Catalog No.:BCC3466
CAS No.:22838-58-0
- Miconazole nitrate
Catalog No.:BCC9047
CAS No.:22832-87-7
- Hypoglaunine A
Catalog No.:BCN3086
CAS No.:228259-16-3
- Boc-Met-OH.DCHA
Catalog No.:BCC2602
CAS No.:22823-50-3
- Alisol K 23-acetate
Catalog No.:BCN3363
CAS No.:228095-18-9
- 3-(4-Hydroxy-3,5-dimethoxyphenyl)-1,2-propanediol
Catalog No.:BCN1480
CAS No.:22805-15-8
- 1,2,3,7-Tetramethoxyxanthone
Catalog No.:BCN7519
CAS No.:22804-52-0
- 1-Hydroxy-2,3,5-trimethoxyxanthone
Catalog No.:BCN6569
CAS No.:22804-49-5
- Ac-D-Trp-OH
Catalog No.:BCC3116
CAS No.:2280-01-5
- Ecdysterone 2,3:20,22-diacetonide
Catalog No.:BCN5074
CAS No.:22798-98-7
- Ecdysterone 20,22-monoacetonide
Catalog No.:BCN5073
CAS No.:22798-96-5
- 9-Epiblumenol B
Catalog No.:BCN5075
CAS No.:22841-42-5
- VULM 1457
Catalog No.:BCC7533
CAS No.:228544-65-8
- Ki8751
Catalog No.:BCC1116
CAS No.:228559-41-9
- Anisomycin
Catalog No.:BCC7007
CAS No.:22862-76-6
- 6-Acetonyldihydrochelerythrine
Catalog No.:BCN5076
CAS No.:22864-92-2
- Famprofazone
Catalog No.:BCC3779
CAS No.:22881-35-2
- Silymarin
Catalog No.:BCN6299
CAS No.:22888-70-6
- 4-Amino-3,5-dichloropyridine
Catalog No.:BCC8679
CAS No.:22889-78-7
- TAK-779
Catalog No.:BCC4137
CAS No.:229005-80-5
- R 892
Catalog No.:BCC5992
CAS No.:229030-05-1
- Ginkgolic acid C15:1
Catalog No.:BCN2307
CAS No.:22910-60-7
- Neferine
Catalog No.:BCN6338
CAS No.:2292-16-2
Pratensein ameliorates beta-amyloid-induced cognitive impairment in rats via reducing oxidative damage and restoring synapse and BDNF levels.[Pubmed:25748315]
Neurosci Lett. 2015 Apr 10;592:48-53.
This study was designed to investigate the protective effect of Pratensein against cognitive impairment induced by amyloid beta (1-42) (Abeta1-42) in rats. Abeta1-42 peptide was injected bilaterally in the hippocampus of rat. Next, Pratensein was administered orally for 3 weeks. Our findings demonstrated that treatment with Pratensein ameliorated learning and memory deficits in Abeta1-42 rat model of AD. Pratensein treatment significantly attenuated neuronal degeneration and apoptosis in hippocampus. Moreover, the over-expression in IL-1beta and TNF-alpha as well as the extensive astrogliosis and microgliosis in hippocampus induced by Abeta1-42 were significantly reduced following administration of Pratensein. Concomitantly, Pratensein treatment significantly suppressed the activation of NF-kappaB in hippocampus. In addition, Pratensein was able to increase the levels of synaptophysin and brain-derived neurotrophic factor (BDNF). These results indicate that Pratensein could significantly ameliorate Abeta1-42-induced spatial learning and memory impairment through reducing neuroinflammation via inhibition of glial activation and NF-kappaB activation, and restoring synapse and BDNF levels, suggesting that administration of Pratensein could likely provide a therapeutic approach for AD.
Flavonoids induce the expression of acetylcholinesterase in cultured osteoblasts.[Pubmed:27019979]
Chem Biol Interact. 2016 Nov 25;259(Pt B):295-300.
Flavonoids, a group of natural compounds mainly derived from plants, are known to possess osteogenic effects in bone cells. Here, we aimed to test if flavonoid could induce a cholinergic enzyme, acetylcholinesterase (AChE), as well as bone differentiation. In cultured rat osteoblasts, twenty flavonoids, deriving from Chinese herbs and having known induction of alkaline phosphatase (ALP(1)) expression, were tested for its induction activity on AChE expression. Eleven flavonoids showed the induction, and five of them had robust activation of AChE expression, including baicalin, calycosin, genistin, hyperin and Pratensein: the induction of AChE included the levels of mRNA, protein and enzymatic activity. Moreover, the flavonoid-induced AChE expression in cultured osteoblast was in proline-rich membrane anchor (PRiMA)-linked tetrameric globular form (G4) only. In parallel, the expression of PRiMA was also induced by the application of flavonoids. The flavonoid-induced AChE in the cultures was not affected by estrogen receptor blocker, ICI 182,780. Taken together, the induction of PRiMA-linked AChE in osteoblast should be independent to classical estrogen signaling pathway.
Protective effect of isoflavones from Trifolium pratense on dopaminergic neurons.[Pubmed:18675857]
Neurosci Res. 2008 Oct;62(2):123-30.
In the present study, protective effect of five isoflavones (formononetin, daidzein, Pratensein, calycosin and irilone) from Trifolium pratense on lipopolysaccharide-induced dopaminergic neurodegeneration was studied for the first time. The results showed that all five isoflavones attenuated LPS-induced decrease in dopamine uptake and the number of dopaminergic neurons in a dose-dependent manner in rat mesencephalic neuron-glia cultures. Moreover, they also significantly inhibited LPS-induced activation of microglia and production of tumor necrosis factor-alpha, nitric oxide and superoxide in mesencephalic neuron-glia cultures and microglia-enriched cultures. In addition, the rank order of protective potency of five isoflavones was: Pratensein>daidzein>calycosin>formononetin>irilone. This study suggested that all five isoflavones protected dopaminergic neurons against LPS-induced injury through inhibition of microglia activation and proinflammatory factors generation.
Characterization of the isoflavone pratensein as a novel transcriptional up-regulator of scavenger receptor class B type I in HepG2 cells.[Pubmed:19571401]
Biol Pharm Bull. 2009 Jul;32(7):1289-94.
Scavenger receptor class B type I (SR-BI), as well as its human homologue CLA-1, plays an important role in reverse cholesterol transport (RCT) as high density lipoprotein (HDL) receptor. Using a previously developed cell-based screening model for CLA-1 up-regulators, Pratensein, was shown to present activity in elevating CLA-1 transcriptional level. In this study, three other isoflavones including formononetin, genistein and daidzein were also shown to up-regulate CLA-1 transcriptional activity in the cell-based reporter assay. The effects of Pratensein on up-regulating CLA-1 expression were demonstrated at both mRNA and protein levels, and validated by its increasing of 1,1'-dioctadecyl-3,3,3',3'-tetramethylindocarbocyanine perchlorate-labeled (DiI)-HDL uptake in HepG2 cells. Furthermore, the cis-elements responsible for the Pratensein up-regulatory effects were mapped to the -1055/-182 bp fragment of CLA-1 promoter in HepG2 cells. These findings might provide a new molecular mechanism by which isoflavones potentially prevent atherosclerosis.
